Last updated: September 1, 2026
Alteplase remains a strategically important thrombolytic despite its age, generic-like price pressure, and growing competition from tenecteplase. Roche’s Genentech markets alteplase in the United States as Activase for acute ischemic stroke, acute myocardial infarction and pulmonary embolism, and as Cathflo Activase for catheter clearance. The products retain regulatory and manufacturing advantages, but their commercial position is exposed to hospital budget controls, supply interruptions, changing stroke protocols and potential substitution by tenecteplase.
The U.S. alteplase market is mature rather than expansionary. Public Roche reporting does not disclose standalone Activase or Cathflo revenue, so the financial trajectory must be assessed through product age, indication volumes, pricing, hospital demand and competitive substitution rather than a verified product-level revenue series.
What products contain alteplase and who markets them?
Alteplase is recombinant human tissue plasminogen activator, or rtPA. In the United States, Genentech, a Roche company, markets the principal branded products.
| Product |
Active ingredient |
Main use |
U.S. regulatory status |
| Activase |
Alteplase |
Acute ischemic stroke, acute myocardial infarction, pulmonary embolism |
Biologics license approved by FDA |
| Cathflo Activase |
Alteplase |
Restoration of function to central venous access devices |
Biologics license approved by FDA |
Activase received its first U.S. approval for acute myocardial infarction in 1987. FDA later approved it for pulmonary embolism and acute ischemic stroke. Cathflo was approved in 1998 for catheter occlusion. The products are supplied as sterile, lyophilized formulations that require reconstitution before administration (FDA, 2023a; FDA, 2023b).
Alteplase is produced through recombinant mammalian-cell technology. The manufacturing process includes cell culture, purification, viral safety controls, formulation and aseptic filling. These requirements create a higher barrier than conventional small-molecule generic manufacturing.
How large is the alteplase market?
No current public source provides a complete global or U.S. revenue figure for alteplase across Activase, Cathflo, hospital purchasing channels and international products. Roche reports sales by broader commercial categories and does not consistently publish separate Activase or Cathflo revenue.
The market has four demand pools:
- Acute ischemic stroke.
- Pulmonary embolism.
- Acute myocardial infarction, now a smaller use because primary percutaneous coronary intervention has replaced thrombolysis in many settings.
- Catheter clearance, primarily through Cathflo.
Stroke is the most strategically important acute-care indication. Treatment volume depends on the number of eligible patients arriving within the treatment window, stroke-center capacity, ambulance routing and institutional protocols. Catheter clearance is less clinically visible but provides recurring hospital demand because Cathflo is used in oncology, intensive care, dialysis and other catheter-dependent settings.
What drives alteplase revenue?
| Driver |
Commercial effect |
| Stroke incidence and treatment rates |
Supports volume growth |
| Hospital stroke-center expansion |
Supports use in eligible patients |
| Door-to-needle performance |
Increases treatment penetration |
| Reimbursement and bundled hospital payments |
Limits price expansion |
| Tenecteplase adoption |
Creates substitution risk |
| Product shortages |
Can reduce sales and shift hospitals to alternatives |
| Cathflo catheter volume |
Provides recurring demand outside acute thrombolysis |
| Institutional contracts |
Pressure net price and margins |
The product’s financial profile is likely characterized by stable or declining volume in legacy indications, offset by persistent demand in stroke and catheter clearance. Net pricing is constrained by hospital group purchasing organizations, government reimbursement and therapeutic alternatives.
What is the financial trajectory for alteplase?
Alteplase moved through three commercial phases.
1987 to the early 2000s: rapid clinical adoption
Activase benefited from first-mover status in thrombolytic therapy and expansion into multiple acute-care indications. The product established a large installed base in hospitals and became embedded in stroke protocols.
The 2000s to the late 2010s: mature branded biologic
By this period, alteplase had lost primary patent exclusivity and operated as a mature branded biologic. The commercial base remained protected by clinical familiarity, hospital protocols, regulatory approvals and manufacturing complexity rather than by a strong current composition-of-matter patent position.
Cathflo added a separate recurring revenue stream. Its use did not depend on emergency thrombolysis volumes and helped diversify the franchise.
The 2020s: supply sensitivity and class substitution
The current market is shaped by hospital shortages, manufacturing constraints and growing interest in tenecteplase. Alteplase demand remains substantial, but purchasing decisions increasingly consider:
- availability of 50-mg and 100-mg vials;
- wastage from weight-based dosing;
- preparation time;
- need for infusion after the initial bolus;
- stroke-network protocols;
- price and contracting terms;
- clinical evidence supporting tenecteplase.
Roche’s annual reports identify established products as part of a broader mature portfolio, but do not provide a separate Activase or Cathflo revenue line. This prevents a defensible calculation of annual product revenue, compound annual growth or margin by indication (Roche, 2024).
What is the FDA regulatory status of alteplase?
Activase and Cathflo are licensed biologic products. Their U.S. regulatory status is established across several indications.
| Product |
Indication |
Regulatory position |
| Activase |
Acute ischemic stroke |
Approved |
| Activase |
Acute myocardial infarction |
Approved |
| Activase |
Pulmonary embolism |
Approved |
| Cathflo Activase |
Central venous catheter occlusion |
Approved |
Alteplase is administered intravenously. Activase dosing varies by indication, body weight and clinical protocol. Stroke treatment generally requires an initial bolus followed by infusion. Cathflo uses a low-dose catheter-directed approach and is withdrawn after restoration of catheter function.
FDA labeling identifies serious bleeding, including intracranial hemorrhage, as the principal safety risk. Eligibility screening, blood-pressure management, imaging and timing requirements limit the treatable population (FDA, 2023a).
What patents protect alteplase and when did exclusivity expire?
Alteplase’s core U.S. patent protection expired many years ago. The original estate covered recombinant production, the protein and related therapeutic use. The remaining commercial protection is primarily regulatory, manufacturing-based and operational rather than a current broad blocking patent.
| Protection category |
Commercial relevance |
| Original recombinant-protein patents |
Expired |
| Production-cell and manufacturing patents |
Historical importance; individual claims require claim-by-claim review |
| Formulation patents |
Limited relevance where expiration has occurred |
| Method-of-use patents |
Some historical value; indication-specific claims may have expired |
| Biologic license |
Continues independently of patent expiration |
| Trade secrets and process know-how |
Important manufacturing barrier |
| Supply-chain qualification |
Important hospital and regulatory barrier |
Because Activase is a biologic, it is not treated like a conventional small molecule under the Hatch-Waxman Orange Book framework. Biologic reference products are tracked through the Purple Book, and a biosimilar applicant generally follows the Public Health Service Act section 351(k) pathway rather than filing an abbreviated new drug application with a Paragraph IV certification (FDA, 2024a; FDA, 2024b).
Is alteplase listed in the Orange Book?
The central reference product is a biologic licensed under a biologics license application, not an ordinary small-molecule new drug application. The relevant regulatory exclusivity and biosimilar information is therefore found through the Purple Book and the reference product’s biologics license records, not through a conventional Orange Book patent table.
This distinction materially reduces the relevance of Paragraph IV litigation. A biosimilar applicant does not use a standard ANDA Paragraph IV challenge to clear alteplase patents.
Are there alteplase biosimilars or generic competitors?
As of the latest publicly established U.S. regulatory information through 2024, the United States had no FDA-approved alteplase biosimilar broadly competing with Activase or Cathflo. The absence of an approved biosimilar supports continued brand control, but it does not create the same level of exclusivity as a live composition patent.
Potential competitors face several barriers:
- demonstration of analytical similarity for a complex glycoprotein;
- comparative pharmacokinetic and pharmacodynamic evidence;
- clinical justification for thrombolytic use;
- aseptic manufacturing and viral safety requirements;
- hospital formulary adoption;
- liability concerns related to intracranial bleeding;
- supply reliability for emergency-care products.
Outside the United States, alteplase products and recombinant tPA versions may be marketed by other manufacturers. International competition does not automatically translate into U.S. approval or U.S. hospital access.
Which companies are challenging alteplase commercially?
The principal competitive threat is tenecteplase, not a conventional generic alteplase.
Tenecteplase is a genetically modified form of tissue plasminogen activator with greater fibrin specificity and a longer plasma half-life. Its single-bolus administration can reduce treatment complexity compared with alteplase, which generally requires a bolus followed by infusion.
As of 2024, tenecteplase had U.S. approval for acute myocardial infarction under the TNKase brand but had not yet received U.S. approval for acute ischemic stroke. Stroke evidence and guideline activity were nevertheless driving hospital evaluation of tenecteplase as an alteplase alternative (FDA, 2024c; Kleindorfer et al., 2023).
The competitive set includes:
| Competitor |
Mechanism or role |
Risk to alteplase |
| Tenecteplase |
Modified tPA, single bolus |
High in stroke and emergency protocols |
| Reteplase |
Modified recombinant tPA |
Relevant in selected thrombolytic uses |
| Mechanical thrombectomy |
Endovascular treatment |
Reduces reliance in large-vessel occlusion pathways |
| Catheter-clearing alternatives |
Mechanical, saline and other agents |
Limited but relevant to Cathflo |
| Supportive or interventional care |
Indication-specific alternatives |
Reduces thrombolytic use in selected patients |
Tenecteplase creates the greatest commercial pressure because it can be positioned as a workflow improvement, not merely as a lower-priced substitute.
What formulation patents protect Activase and Cathflo?
The commercial formulations are relatively simple compared with long-acting biologics, but they require controlled production and sterile presentation.
Activase is sold in larger vials for systemic thrombolysis. Cathflo is supplied in a 2-mg vial for catheter clearance. Product differentiation comes from dose presentation, reconstitution instructions, stability, labeling, validated manufacturing and hospital familiarity.
No publicly established, currently blocking formulation patent has been identified as the principal basis for U.S. market exclusivity. The more durable barriers are process validation, regulatory comparability, emergency-care reliability and institutional trust.
What patent litigation and Paragraph IV disputes affect alteplase?
There is no major active U.S. Paragraph IV litigation framework surrounding Activase comparable to litigation involving branded small-molecule drugs. The reason is structural: alteplase is a biologic reference product, and biosimilar applicants use the Biologics Price Competition and Innovation Act pathway.
A complete litigation review would distinguish:
- patent cases involving the original Genentech recombinant tPA estate;
- disputes over later manufacturing or formulation patents;
- regulatory challenges involving biosimilar applications;
- commercial disputes over hospital supply and contracting.
The historical core patent estate is no longer the primary commercial constraint. Current risk is more likely to arise from regulatory approval, manufacturing comparability, supply continuity or clinical adoption of competing thrombolytics.
How strong is the alteplase patent estate?
The patent estate is weak as a conventional exclusivity asset but strong as a manufacturing and regulatory franchise.
| Dimension |
Assessment |
| Core composition patents |
Expired or commercially exhausted |
| Current patent-based price protection |
Low |
| Biosimilar entry barrier |
Moderate to high |
| Manufacturing complexity |
High |
| Brand and clinical adoption |
High |
| Hospital switching costs |
Moderate |
| Substitution risk from tenecteplase |
Increasing |
| Litigation-based defense |
Limited compared with newer biologics |
The estate’s value depends less on patent term and more on the difficulty of proving biosimilarity, securing reliable supply and persuading hospitals to change emergency protocols.
What generic launch scenarios exist for alteplase?
Three scenarios are commercially relevant.
Scenario 1: No U.S. biosimilar launch
Activase and Cathflo retain the reference-product position. Roche faces contracting pressure but benefits from clinical familiarity and the absence of an approved direct substitute.
Scenario 2: One approved alteplase biosimilar
A single biosimilar could pressure hospital prices, especially in catheter clearance and high-volume stroke systems. Automatic substitution would depend on FDA interchangeability status, payer policy, state law and hospital formulary decisions.
Scenario 3: Tenecteplase-led substitution
Hospitals shift stroke protocols toward tenecteplase because of single-bolus administration, reduced preparation burden and favorable clinical evidence. Alteplase remains available for patients or indications where clinicians prefer its established label and evidence base.
The third scenario may be more consequential than a traditional generic launch because it can reduce demand without requiring an alteplase biosimilar to enter the market.
What is the geographic coverage of alteplase?
Alteplase is marketed internationally through Roche, Genentech and regional partners or licensees, subject to country-specific approvals and reimbursement. The product is most commercially defensible in markets with:
- organized stroke systems;
- access to emergency imaging;
- reimbursement for thrombolysis;
- centralized hospital procurement;
- established catheter-based care;
- validated recombinant biologic manufacturing standards.
Pricing, tender systems and local competitors vary substantially. U.S. economics are shaped by hospital contracts and emergency-care reimbursement. European markets are more exposed to national procurement and tender pricing. Emerging markets may have greater volume sensitivity to lower-cost recombinant tPA products.
What manufacturing and intellectual-property barriers protect alteplase?
Manufacturing is the principal non-patent barrier. Alteplase production requires:
- recombinant mammalian-cell expression;
- control of glycosylation and protein folding;
- purification of a fibrinolytic protein;
- removal or control of process impurities;
- viral safety validation;
- sterile fill-finish;
- stability testing;
- batch consistency.
Small changes in glycosylation, aggregation, potency or impurity profile can affect regulatory comparability. The emergency-use setting also makes supply reliability commercially important. A low-cost entrant that cannot maintain uninterrupted supply may fail to secure hospital adoption.
Key Takeaways
- Alteplase is a mature recombinant biologic marketed in the United States as Activase and Cathflo Activase by Genentech, Roche’s U.S. biotechnology subsidiary.
- The core patent estate is historically important but no longer provides meaningful broad patent exclusivity.
- Activase and Cathflo are biologics, so biosimilar regulation and Purple Book status are more relevant than conventional Orange Book Paragraph IV litigation.
- No FDA-approved U.S. alteplase biosimilar was established through 2024.
- Roche does not publicly disclose standalone Activase or Cathflo revenue, preventing a verified product-level financial forecast.
- Stroke and catheter clearance are the principal current demand pools.
- Tenecteplase is the leading commercial threat because single-bolus administration can improve hospital workflow.
- Manufacturing complexity, clinical adoption and supply reliability provide stronger protection than current patent term.
- The highest-value commercial risk is protocol-driven substitution by tenecteplase, not a classic generic launch.
FAQs
Does alteplase still have patent protection in the United States?
The original broad patent protection for recombinant alteplase expired long ago. Current commercial protection is based mainly on biologic regulation, manufacturing know-how, product reliability and clinical adoption.
Is Activase interchangeable with tenecteplase?
No. Interchangeability is a regulatory designation associated with biosimilars and reference biologics. Tenecteplase is a different active biologic product with distinct labeling, dosing and clinical evidence.
Is Cathflo exposed to the same competitive risks as Activase?
Cathflo faces less direct tenecteplase risk because it is used for catheter clearance rather than systemic thrombolysis. Its main risks are hospital price controls, competing catheter-management practices and any future alteplase biosimilar.
Why is alteplase expensive despite expired patents?
Biologic manufacturing, sterile presentation, emergency-care supply requirements, hospital contracting and limited approved competition can support prices after patent expiry.
Could an alteplase biosimilar automatically replace Activase?
Not necessarily. Replacement would depend on FDA approval, possible interchangeability designation, state substitution rules, payer policy, hospital formulary decisions and demonstrated supply reliability.
References
-
Food and Drug Administration. (2023a). Activase alteplase prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2023b). Cathflo Activase alteplase prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024a). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024b). Biological product patent litigation and the Biologics Price Competition and Innovation Act. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024c). TNKase tenecteplase prescribing information. U.S. Department of Health and Human Services.
-
Kleindorfer, D. O., Towfighi, A., Ch Certner, J., et al. (2023). 2023 guideline for the early management of patients with acute ischemic stroke. Stroke, 54(7), e364-e467.
-
Roche Holding Ltd. (2024). Annual report 2023. Roche.
